Patents Represented by Attorney, Agent or Law Firm Paul J. Gaylo
  • 2-acylaminopropanamides as growth hormone secretagogues
    Patent number: 5773441
    Abstract: This invention provides a series of novel substituted propanamides which are useful in the a physiological condition which may be modulated by an increase in growth hormone. This invention also provides methods for the treatment of such physiological conditions which comprise administering a growth hormone secretagogue as described in the present invention in combination with growth hormone releasing hormone.
    Type: Grant
    Filed: August 20, 1996
    Date of Patent: June 30, 1998
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Jeffrey Alan Dodge
  • Benzylidene rhodanines
    Patent number: 5747517
    Abstract: This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with .beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.
    Type: Grant
    Filed: September 11, 1996
    Date of Patent: May 5, 1998
    Assignee: Eli Lilly and Company
    Inventors: Jill A. Panetta, Michael L. Phillips, Jon K. Reel, John K. Shadle, Sandra K. Sigmund, Richard L. Simon, Celia A. Whitesitt
  • Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
    Patent number: 5744482
    Abstract: Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.
    Type: Grant
    Filed: October 5, 1994
    Date of Patent: April 28, 1998
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, Kirk W. Johnson, Lee A. Phebus
  • Amyloid precursor protein protease
    Patent number: 5733768
    Abstract: This invention provides an APP-cleaving protein and related nucleic acid compounds. The invention also provides methods, materials and assays. The compounds of this invention will further the characterization of neurological diseases such as Alzheimer's disease and Down's syndrome.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: March 31, 1998
    Assignee: Eli Lilly and Company
    Inventors: Eric P. Dixon, Edward M. Johnstone, Sheila P. Little, Franklin H. Norris
  • Serotonin receptor protein and related nucleic acid compounds
    Patent number: 5698444
    Abstract: This invention describes a novel human serotonin receptor, designated 5-HT.sub.2B. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: December 16, 1997
    Assignee: Eli Lilly and Company
    Inventors: Melvyn Baez, Jonathan D. Kursar
  • Human brain sodium dependent inorganic phosphate cotransproter and related nucleic acid compounds
    Patent number: 5686266
    Abstract: This invention describes a novel human brain Na.sup.+ -dependent inorganic phosphate cotransporter, designated the hBNPI protein. This invention also encompasses nucleic acids encoding this protein, or a fragment thereof, as well as methods employing this protein and the nucleic acid compounds.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: November 11, 1997
    Assignee: Eli Lilly and Company
    Inventors: Binhui Ni, Steven M. Paul
  • Non-peptide tachykinin receptor antagonists
    Patent number: 5684033
    Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 4, 1997
    Assignee: Eli Lilly and Company
    Inventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
  • DNA sequences encoding porcine pancreatic carboxypeptidase B
    Patent number: 5672496
    Abstract: DNA encoding porcine Pro-carboxypeptidase B, vectors comprising the DNA and host cells transformed with the vectors are useful for production of porcine carboxypeptidase B
    Type: Grant
    Filed: August 13, 1996
    Date of Patent: September 30, 1997
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey T. Fayerman, David P. Greenen, Charles L. Hershberger, Jeffrey L. Larson, Jane L. Sterner, Haichao Zhang
  • Non-peptide tachykinin receptor antagonists
    Patent number: 5670499
    Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 23, 1997
    Assignee: Eli Lilly and Company
    Inventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
  • Antibody drug-conjugates
    Patent number: 5665358
    Abstract: Immunoconjugates of antibodies or antigen-recognizing fragments of antibodies and monovalent cytotoxic drug derivatives make use of .beta.-alanine derived linkers wherein the antibody or fragment thereof is attached to the linker's carboxy group via an ester or amide group and the drug is attached through the linker's 2-position methylene group. Intermediates, compositions and methods of use also are provided.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: September 9, 1997
    Assignee: Eli Lilly and Company
    Inventors: Russell L. Barton, Deborah L. Guttman-Carlisle, Gary A. Koppel
  • Heterocyclic neuropeptide Y receptor antagonists
    Patent number: 5663192
    Abstract: This invention provides methods for treating or preventing a condition associated with an excess of neuropeptide Y which methods comprise administration of one or more substituted benzofurans, benzothiophenes or indoles.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: September 2, 1997
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Antibody-drug conjugates
    Patent number: 5643573
    Abstract: Immunoconjugates of antibodies or antigen-recognizing fragments of antibodies and monovalent cytotoxic drug derivatives make use of .beta.-alanine derived linkers wherein the antibody or fragment thereof is attached to the linker's carboxy group via an ester or amide group and the drug is attached through the linker's 2-position methylene group. Intermediates, compositions and methods of use also are provided.
    Type: Grant
    Filed: October 10, 1995
    Date of Patent: July 1, 1997
    Assignee: Eli Lilly and Company
    Inventors: Russell L. Barton, Deborah L. Guttman-Carlisle, Gary A. Koppel
  • Acid labile immunoconjugate intermediates
    Patent number: 5612474
    Abstract: Trityl derivatives useful as "linkers" for preparation of imunoconjugates comprising drugs end antibodies are provided. Immunoconjugates and processes for their preparation and use are also provided. This invention also provides for prodrugs comprising a substituted trityl group conjugated with a drug of choice as well as methods of using the imunoconjugates and prodrugs of this invention.
    Type: Grant
    Filed: June 30, 1994
    Date of Patent: March 18, 1997
    Assignee: Eli Lilly and Company
    Inventor: Vinod F. Patel
  • Pyrrolidinyl tachykinin receptor antagonists
    Patent number: 5607947
    Abstract: This invention provides a novel series of substituted pyrrolidines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: March 4, 1997
    Assignee: Eli Lilly and Company
    Inventor: Philip A. Hipskind
  • Chimeric antibodies directed against a human glycoprotein antigen
    Patent number: 5580774
    Abstract: The present invention discloses novel chimeric monoclonal antibodies, directed against proteoglycans of human melanoma cells, having antigen-specific variable regions of defined amino acid sequences. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are provided. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also provided.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: December 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: Lisa S. Beavers, Thomas F. Bumol, Robert A. Gadski
  • Antitumor compositions and methods of treatment
    Patent number: 5565494
    Abstract: This invention provides certain benzenesulfonamide derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these benzenesulfonamide derivatives in combination with a carrier, and processes for preparing the benzenesulfonamide derivatives.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: October 15, 1996
    Assignee: Eli Lilly and Company
    Inventors: Gerald B. Grindey, Cora S. Grossman, J. Jeffry Howbert, Karen L. Lobb, James E. Ray, John E. Toth
  • 2-acylaminopropanamides as tachykinin receptor antagonists
    Patent number: 5565568
    Abstract: This invention provides a series of novel substituted propanamides which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: October 15, 1996
    Assignee: Eli Lilly and Company
    Inventors: Sung-Yong S. Cho, Philip A. Hipskind, J. Jeffry Howbert, Brian S. Muehl, James A. Nixon
  • Hexamethyleneiminyl tachykinin receptor antagonists
    Patent number: 5563133
    Abstract: This invention provides a novel series of substituted hexamethyleneimines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventor: Philip A. Hipskind
  • Phospholipase A.sub.2 inhibitors
    Patent number: 5563164
    Abstract: This invention provides methods for the treatment or prevention of Alzheimer's disease in a mammal which comprises administering to a mammal in need thereof an effective amount of an inhibitor of phospholipase A.sub.2. This invention also provides a series of compounds which are useful as inhibitors of phospholipases A.sub.2, especially cytosolic phospholipase A.sub.2.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventors: James A. Clemens, Michael J. Sofia, Diane T. Stephenson
  • Antibody-drug conjugates
    Patent number: 5556623
    Abstract: Immunoconjugates of antibodies or antigen-recognizing fragments of antibodies and monovalent cytotoxic drug derivatives make use of .beta.-alanine derived linkers wherein the antibody or fragment thereof is attached to the linker's carboxy group via an ester or amide group and the drug is attached through the linker's 2-position methylene group. Intermediates, compositions and methods of use also are provided.
    Type: Grant
    Filed: March 30, 1993
    Date of Patent: September 17, 1996
    Assignee: Eli Lilly and Company
    Inventors: Russell L. Barton, Deborah L. Guttman-Carlisle, Gary A. Koppel